RxDoctor Payments Data

Joseph Dykes

Nurse Practitioner · Summit, MSNPI 1396123402

Payments from drug & device makers

$474in general payments, 2019–2025

Across 21 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$187
  • AbbVie$62
  • Kowa Pharmaceuticals America, Inc.$45
  • Xeris Pharmaceuticals, Inc.$44
  • Indivior Inc.$32
  • Lilly USA, LLC$23
  • plus $82 from 5 others

What the payments were for

  • Food & beverage$474100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$474 in reported general payments places this provider in the 60th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$16,729
Medicare patients
156
Services billed
1,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide159$117,852
OzempicSemaglutide90$90,694
EliquisApixaban97$67,889
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$34,796
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl182$30,663
XareltoRivaroxaban48$28,579
EntrestoSacubitril/Valsartan24$20,529
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,063$18,884
SuboxoneBuprenorphine Hcl/Naloxone Hcl24$13,962
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$13,413
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$11,482
Lantus SolostarInsulin Glargine,hum.Rec.Anlog101$9,950
JardianceEmpagliflozin17$9,826
Levemir FlexpenInsulin Detemir26$8,346
Gabapentin743$8,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Synthroid$62$119,396172 claims
PfizerEliquis$11$67,88997 claims
Indivior Inc.Suboxone$32$13,96224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Summit

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →